

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scheller, D. *et al.*
Serial No.: **10/565,699**
Filed: 25 January 2006
Title: USE OF ROTIGOTINE FOR THE TREATMENT OF DEPRESSION
Group Art Unit: 1627
Examiner: Carter, Kendra D.
Confirmation No.: 2513
Docket No.: **6102-000009/US/NP**
Client Ref.: **P/Sche/I/4/03**

SUBMITTED ELECTRONICALLY VIA EFS-WEB

27 July 2011

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §1.97(c)

Applicant hereby submits a supplemental Information Disclosure Statement (IDS) under 37 C.F.R. §1.97(c) after the mailing of a first Office action but before the mailing of a final action. Authorization is given to charge the fee set forth in 37 CFR 1.17(p) to Deposit Account No. **08-0750**.

This IDS further supplements the information disclosure statements submitted on 18 November 2010, 10 February 2010, 6 October 2009 and 28 January 2008.

In accordance with 37 C.F.R. §1.97(g) and (h), this submission shall not be construed as representation that a search has been made or as admission that information presented or cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

In accordance with 37 C.F.R. §1.98, Applicant submits herewith (1) a listing on Form PTO-1449 of documents requested to be considered by the Examiner and (2) a legible copy of each listed document, except for U.S. patents and U.S. patent application publications.

Consideration by the Examiner of the present submission is requested.

Should any issue remain, the Examiner is invited to call the undersigned at the telephone number given below.

HARNESS, DICKEY & PIERCE, P.L.C.

/ Molly B. Edwards /

Molly B. Edwards
Attorney for Applicant
Reg. No. 68,013
Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
314.446.7682 (direct)
314.726.7501 (fax)